*  FDA Approves Mercaptopurine Oral Suspension for Acute Lymphoblastic Leukemia - The ASCO Post
The starting dose of mercaptopurine in multiagent combination chemotherapy maintenance regimens is 1.5 to 2.5 mg/kg (50 to 75 ... Heterogeneity of the Estrogen Receptor and Risk of Death in Breast Cancer. Study Describes Structure of Tumor Herpes Virus ... Triple Inhibitory Neoadjuvant Therapy in HER2-Positive, ER-Positive Breast Cancer FDA Approves Olaparib for Germline BRCA- ... Triple Inhibitory Neoadjuvant Therapy in HER2-Positive, ER-Positive Breast Cancer View More ...
  http://www.ascopost.com/issues/may-15-2014/fda-approves-mercaptopurine-oral-suspension-for-acute-lymphoblastic-leukemia/
*  Search of: inflammatory breast cancer AND Topoisomerase - List Results - ClinicalTrials.gov
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer. *Inflammatory Breast Cancer ... Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer. *Breast ... Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer. *Breast Cancer ... Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer. *Breast Cancer ...
  https://clinicaltrials.gov/ct2/results?term=inflammatory+breast+cancer+AND+Topoisomerase
*  Search of: inflammatory breast cancer AND Modulators - List Results - ClinicalTrials.gov
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer. *Inflammatory Breast Cancer ... Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer. *Breast Cancer ... AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer. *Breast Cancer ... Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer. *Breast Cancer ...
  https://clinicaltrials.gov/ct2/results?term=inflammatory+breast+cancer+AND+Modulators
*  Chemotherapy in Inflammatory Breast Cancer | Springer for Research & Development
Without systemic therapy, the 5-year survival was 4 %. Since 1970s, with the introduction of neoadjuvant chemotherapy in the ... Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy. Ten-year results from the ... High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow ... Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate ...
  https://rd.springer.com/chapter/10.1007/978-0-85729-991-8_6
*  Adjuvant therapy of breast cancer 1971-1981 | SpringerLink
Band PR, Tormey DC, Temkin N: Induction chemotherapy and maintenance chemohormone therapy in metastatic breast cancer (abstract ... Rivkin S, Glucksberg H, Rasmussen S: Adjuvant chemotherapy for operable breast cancer with positive nodes (abstract). Breast ... One short-term chemotherapy in primary breast cancer: 12 year follow-up in series 1 of the Scandinavian Adjuvant Chemotherapy ... Carbone PP: Chemotherapy in the treatment strategy of breast cancer. Cancer 36: 633-637, 1975.PubMedGoogle Scholar ...
  https://link.springer.com/article/10.1007/BF01805719
*  Protocols and Video Articles Authored by Kazuhide Sato (Translated to Korean)
CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung ... and its maintenance chemotherapy (pemetrexed + bevacizumab). The cases of patients with breast metastasis from other organs are ... bevacizumab and its maintenance chemotherapy is feasible and well tolerated for breast metastasis from a lung adenocarcinoma ... maintenance chemotherapy (BEV and erlotinib) was performed. Chemotherapy was continued for 9 months until the patient was in a ...
  https://www.jove.com/author/Kazuhide_Sato?language=Korean
*  immunotherapy | Cancer.Net
... a new targeted therapy for treating advanced breast cancer, an immunotherapy-chemotherapy combination that slows lung cancer ... and Maintenance Chemotherapy for Rhabdomyosarcoma. Language English ... ASCO Annual Meeting 2018: New Insight Into Lynch Syndrome, Finding and Treating Lung Cancer, a New Targeted Therapy for Breast ... ASCO Annual Meeting 2018: Less Treatment Needed for Some Patients With Breast Cancer and Kidney Cancer, Immunotherapy for Non- ...
  https://www.cancer.net/tags/immunotherapy
*  Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer - ONA
... alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer. ... Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast ... In a secondary analysis of the BEATE and INVEST study, ... Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer. *New Hypertension Threshold Guides Blood Pressure ... More in Breast Cancer. Factors Affecting Employment Participation in Early-stage Breast Cancer Researchers conducted a ...
  https://www.oncologynurseadvisor.com/breast-cancer/triplet-regimen-highly-active-for-triple-negative-breast-cancer/article/509627/
*  A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With...
Pregnant or breast feeding. For males and females of child-producing potential, inability to use effective contraceptive ... Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin Phase 2 ... Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin Other Names: ... A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With ...
  https://clinicaltrials.gov/show/NCT01908777
*  mess0063
Title: Computer Model Predicts Long-term Maintenance Chemotherapy is Possible in Breast Cancer: Clinical Trial at Five Year ...
  http://www.ccl.net/chemistry/announcements/conferences/oldconferences/conferencelist/mess0063.shtml
*  Management of Metastatic Triple-Negative Breast Cancer | SpringerLink
Triple-negative breast cancer (TNBC) which is defined by the lack of expression of estrogen receptor (ER) and progesterone ... Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast ... Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005; ... Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer ...
  https://link.springer.com/chapter/10.1007/978-3-319-69980-6_8?no-access=true
*  Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and...
Intradialytic Progressive Resistance Training for Maintenance Haemodialysis Patients. The purpose of this study is to ... breast cancer patients during chemotherapy. To determine the effect of the exercise itself beyond potential psychosocial ... Breast Cancer Track and monitor developments in breast cancer research and commercial development. Follow the tabs above to ... More From BioPortfolio on "Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: ...
  https://www.bioportfolio.com/resources/trial/65853/Progressive-Resistance-Training-Versus-Relaxation-for-Breast-Cancer-Patients-During-Chemotherapy-Biological.html
*  Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study - Zurich...
Maintenance Infos Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional ... Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast ... Download PDF 'Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study ... Sixteen pathologists of the European Working Group for Breast Screening Pathology reviewed the core biopsies of breast cancers ...
  https://www.zora.uzh.ch/id/eprint/103692/
*  Maintenance Treatment with Interferon in Multiple Myeloma | Springer for Research & Development
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group ... fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51: 111-6PubMedCrossRefGoogle Scholar ... Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow ... Cost-effectiveness of adjuvant intraportal chemotherapy in colorectal cancer. J Clin Gastroenterol 1996; 23: 269-74PubMed ...
  https://rd.springer.com/article/10.2165/00044011-199714050-00008
*  Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer - Full Text View - ClinicalTrials.gov
No malignancies within previous 5 years other than non-melanoma skin cancer, in-situ cervical cancer, in-situ ductal breast ... Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer. The safety and scientific validity ... Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer. Study Start Date :. August ... followed by chemotherapy alone given three times over an additional 9 weeks. Follow-up begins with an examination at the end of ...
  https://clinicaltrials.gov/ct2/show/NCT01613469?recr=Open&cond=%22Rectal+Neoplasms%22&rank=18
*  DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer - Tabular View - ClinicalTrials...
... thereby diverting energy from growth to maintenance. Accordingly, the currently available preclinical evidence suggests that ... DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer (DIRECT). The safety and ... DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer. ... DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer. ...
  https://clinicaltrials.gov/ct2/show/record/NCT02126449?term=fasting+mimicking+diet
*  A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer - Full Text View -...
Histologically or cytologically confirmed locally advanced or metastatic breast cancer. *One and only one prior chemotherapy ... After treatment phase, weekly bavituximab maintenance is continued until disease progression.. Outcome Measures ... Breast Neoplasms. Neoplasms by Site. Neoplasms. Breast Diseases. Skin Diseases. Docetaxel. Antibodies, Monoclonal. ... A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer. The safety and scientific ...
  https://clinicaltrials.gov/show/NCT00669591
*  My Lifestyle Intervention of Food and Exercise - Full Text View - ClinicalTrials.gov
Completed primary treatments (chemotherapy, radiation, and/or surgical treatment) for breast cancer (with or without ... maintenance therapy) within the last 3 months to 5 years of providing consent ... Breast cancer. Breast cancer prevention. Breast cancer recurrence. Weight loss. Weight management. Overweight. Obesity. ... Breast cancer risk, and risk of related health problems (e.g., heart disease), is highest among women with a history of breast ...
  https://clinicaltrials.gov/ct2/show/NCT01630499?recr=Open&intr=%22Weight+Reduction+Programs%22&rank=5
*  Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy
Plk4 is required for cytokinesis and maintenance of chromosomal stability. P Natl Acad Sci USA. 2010;107:6888-93 ... Breast cancer tissues and corresponding normal breast tissues from breast cancer patients (n=30) were obtained from Tianjin ... Method: The PLK4 mRNA expression was measured in breast cancer tissues and corresponding normal breast tissues from 30 breast ... A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and ...
  http://www.jcancer.org/v07p1125.htm
*  Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy...
... for the treatment of primary breast cancer (BC) has constantly increasing, especially in … ... Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for ... and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 120(2 ... and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 92(1):69-75 ...
  https://www.springermedizin.de/expression-of-m2-macrophage-markers-ykl-39-and-ccl18-in-breast-c/15739288
*  IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma - Full Text View - ClinicalTrials.gov
... every 4 weeks during the maintenance phase for an additional period of up to 12 injections ... IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma. The safety and scientific validity of ... Prior chemotherapy for metastatic breast adenocarcinoma. *Disease-free interval of less than twelve months from the last dose ... with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. ...
  https://clinicaltrials.gov/ct2/show/NCT02614833?term=Prima+BIoMed&rank=5
*  Avastin Plus Commonly Used Chemotherapies Improves the Time Breast Cancer Patients Live Without
... Their Disease Getting Worse
maintenance of blood vessels which is required for a tumour to grow and to spread ( ... Avastin Plus Commonly Used Chemotherapies Improves the Time Breast Cancer Patients Live Without Their Disease Getting Worse. ... 37.9% for Avastin + anthracycline or taxane chemotherapy vs. chemotherapy alone). - There were no new safety signals for ...
  https://www.newswire.ca/news-releases/avastin-plus-commonly-used-chemotherapies-improves-the-time-breast-cancer-patients-live-without-their-disease-getting-worse-537775391.html
*  FDA approves first treatment for breast cancer with a certain inherited genetic mutation - EIN News
... advanced ovarian cancer who have received three or more treatments of chemotherapy, and for the maintenance treatment of ... Approximately 20-25 percent of patients with hereditary breast cancers and 5-10 percent of patients with any type of breast ... negative metastatic breast cancer, who have been previously treated with chemotherapy. Patients with hormone receptor (HR)- ... Breast cancer is the most common form of cancer in the United States. The National Cancer Institute at the National Institutes ...
  https://www.einnews.com/pr_news/426566560/fda-approves-first-treatment-for-breast-cancer-with-a-certain-inherited-genetic-mutation
*  LYNPARZA® (olaparib) in Combination With Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate...
... platinum-based chemotherapy regardless of BRCA mutation status; and for the treatment of gBRCA HER2-negative metastatic breast ... previously treated with three or more lines of chemotherapy; for the maintenance treatment of recurrent ovarian cancer in ... negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. ... ADVERSE REACTIONS-Maintenance Setting Most common adverse reactions (Grades 1-4) in ≥20% of patients in clinical trials of ...
  https://www.businesswire.com/news/home/20180604006429/en/LYNPARZA%C2%AE-olaparib-Combination-Abiraterone-Delayed-Disease-Progression
*  The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients | Clinical Science
BCSCs (breast cancer stem cells) have been shown to be resistant to chemotherapy. However, the mechanisms underlying BCSC- ... The Hh (Hedgehog) pathway is important in the stemness maintenance of CSCs. Nonetheless, it is unknown whether the Hh pathway ... breast cancer stem cell; CCK-8, Cell Counting Kit-8; CAF, cyclophosphamide/adriamycin/fluorouracil; CEF, cyclophosphamide/ ... The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Miao He, Yingzi Fu ...
  http://www.clinsci.org/content/129/9/809